Tailored Phenobarbital Sodium Formulations with Enhanced Stability and Patient-Specific Dosing

This inventive concept presents a novel approach to stabilizing phenobarbital sodium for injection, enabling adjustable ethanol content, improved reconstitution, and patient-specific dosing. The innovations overcome limitations of the original patent, providing a more efficient, safer, and personalized treatment option for neonatal seizure patients.

The original patent for stabilizing phenobarbital sodium for injection has limitations in terms of fixed ethanol content, potential pH instability, and inefficient reconstitution. These limitations can lead to variability in treatment outcomes and patient response. The new inventive concept addresses these issues by introducing adjustable ethanol content, pH-adjusting agents, and optimized reconstitution methods, ensuring a more reliable and effective treatment option.

The new inventive concept involves a lyophilized pharmaceutical composition of phenobarbital or salts thereof, wherein the ethanol content can be adjusted to a predetermined level between 5000 ppm to 70000 ppm. This allows for tailored formulation specific to individual patient needs. Additionally, the composition may include a pH-adjusting agent to maintain a stable pH range of 6.5 to 7.5 during reconstitution. The reconstitution process can be optimized through sonication of the lyophilized powder with the vehicle/diluent for a duration of 1-5 minutes, improving dissolution efficiency. Furthermore, a system for administering the lyophilized pharmaceutical composition can be integrated with a smart injection device that automatically adjusts the injection rate based on real-time patient response data. The advanced purification process involving tandem chromatography and crystallization can reduce total impurities to less than 0.1%.

The new claims introduce a novel adjustable ethanol content feature, pH-adjusting agents, optimized reconstitution methods, and a smart injection device, which are not obvious from the original patent. These innovations provide a significant improvement in stability, efficacy, and patient safety, distinguishing the new inventive concept from the prior art.

Alternative embodiments of the inventive concept could include varying the pH-adjusting agents, using different sonication frequencies or durations, or integrating the smart injection device with other patient monitoring systems. Additionally, the advanced purification process could be modified to incorporate other chromatography or crystallization techniques.

The inventive concept has significant commercial potential in the pharmaceutical industry, particularly in the treatment of neonatal seizure patients. The adjustable ethanol content and patient-specific dosing features can provide a competitive advantage in the market, offering a more effective and personalized treatment option. The smart injection device and advanced purification process can also be marketed as standalone products or integrated into existing pharmaceutical manufacturing lines.